123 related articles for article (PubMed ID: 35514255)
21. Plasma proteome alterations by MAPK inhibitors in BRAF
Babačić H; Eriksson H; Pernemalm M
Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
[TBL] [Abstract][Full Text] [Related]
22. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
23. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.
Tian Y; Guo W
Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Wichmann J; Rynn C; Friess T; Petrig-Schaffland J; Kornacker M; Handl C; Emmenegger J; Eckmann J; Herting F; Frances N; Hunziker D; Krummenacher D; Rüttinger D; Ribeiro A; Bacac M; Brigo A; Hewings DS; Dummer R; Levesque MP; Schnetzler G; Martoglio B; Bischoff JR; Pettazzoni P
Clin Cancer Res; 2022 Feb; 28(4):770-780. PubMed ID: 34782366
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
Mohapatra P; Prasad CP; Andersson T
Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
[TBL] [Abstract][Full Text] [Related]
26. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
[TBL] [Abstract][Full Text] [Related]
27. Loss of Spry1 reduces growth of BRAF
Montico B; Colizzi F; Giurato G; Rizzo A; Salvati A; Baboci L; Benedetti D; Pivetta E; Covre A; Bo MD; Weisz A; Steffan A; Maio M; Sigalotti L; Fratta E
Cell Death Dis; 2020 May; 11(5):392. PubMed ID: 32444628
[TBL] [Abstract][Full Text] [Related]
28. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
29. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
30. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
31. Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?
Bédouelle E; Nguyen JM; Varey E; Khammari A; Dreno B
Dermatology; 2022; 238(3):517-526. PubMed ID: 34818219
[TBL] [Abstract][Full Text] [Related]
32. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.
Wang J; Huang SK; Marzese DM; Hsu SC; Kawas NP; Chong KK; Long GV; Menzies AM; Scolyer RA; Izraely S; Sagi-Assif O; Witz IP; Hoon DSB
J Invest Dermatol; 2015 Feb; 135(2):532-541. PubMed ID: 25243790
[TBL] [Abstract][Full Text] [Related]
34. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
[TBL] [Abstract][Full Text] [Related]
35. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
36. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
[TBL] [Abstract][Full Text] [Related]
37. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.
Chien AJ; Haydu LE; Biechele TL; Kulikauskas RM; Rizos H; Kefford RF; Scolyer RA; Moon RT; Long GV
PLoS One; 2014; 9(4):e94748. PubMed ID: 24733413
[TBL] [Abstract][Full Text] [Related]
38. The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.
Babagana M; Kichina JV; Slabodkin H; Johnson S; Maslov A; Brown L; Attwood K; Nikiforov MA; Kandel ES
Mol Carcinog; 2020 Jan; 59(1):5-14. PubMed ID: 31571292
[TBL] [Abstract][Full Text] [Related]
39. Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors.
Leclair HM; Tardif N; Paris A; Galibert MD; Corre S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708687
[TBL] [Abstract][Full Text] [Related]
40. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.
Webster MR; Fane ME; Alicea GM; Basu S; Kossenkov AV; Marino GE; Douglass SM; Kaur A; Ecker BL; Gnanapradeepan K; Ndoye A; Kugel C; Valiga A; Palmer J; Liu Q; Xu X; Morris J; Yin X; Wu H; Xu W; Zheng C; Karakousis GC; Amaravadi RK; Mitchell TC; Almeida FV; Xiao M; Rebecca VW; Wang YJ; Schuchter LM; Herlyn M; Murphy ME; Weeraratna AT
Mol Cell; 2020 Feb; 77(3):633-644.e5. PubMed ID: 31836388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
